|

HALOZYME THERAPEUTICS INC (HALO)

US40637H1095 - Common Stock

39.95  -0.2 (-0.5%)

After market: 39.95 0 (0%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Revenue
YoY % growth
267.6M
36.53%
443.3M
65.66%
660.1M
48.91%
858.13M
30.00%
EBITDA
YoY % growth
147.6M
332.44%
278.9M
88.96%
339M
21.55%
429.16M
26.60%
N/AN/AN/AN/AN/A
EBIT
YoY % growth
144.3M
313.46%
275.9M
91.20%
289.4M
4.89%
371.73M
28.45%
Operating Margin
53.92%62.24%43.84%43.32%
EPS
YoY % growth
0.90
280.00%
1.92
113.33%
2.22
15.62%
2.72
22.74%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 23 Q1 / 24 Q2 / 24 Q3 / 24 Q4 / 24
EPS
Q2Q % growth
0.81
69.58%
Revenue
Q2Q % growth
241.41M
33.01%
EBITDA
Q2Q % growth
133.58M
EBIT
Q2Q % growth
108.99M
43.60%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
0.75
1.35%
0.720.033.96%
Q2 2023
Q2Q % growth
0.74
39.62%
0.640.1015.31%
Q1 2023
Q2Q % growth
0.47 0.49-0.02-3.40%
Q4 2022
Q2Q % growth
0.48
14.29%
0.480.001.02%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2023
Q2Q % growth
216M
3.35%
220.43M-4.43M-2.01%
Q2 2023
Q2Q % growth
221M
45.01%
203.95M17.05M8.36%
Q1 2023
Q2Q % growth
162.1M
38.19%
179.02M-16.92M-9.45%
Q4 2022
Q2Q % growth
181.5M
77.94%
195.9M-14.4M-7.35%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS9.21% 7.84% 0% 2.24%
Revenue3.8% 2.54% 0% 2.22%